- $49.5 BnWorld market, 2023
- $73.3 BnProjected, 2033
- 4%Growth a year (CAGR)
- 1,336Active clinical trials worldwide
Largest countries
Market size in 2023 · growth a year to 2033
-
1
US
$20.8 Bn
2% a year · 42% of the world -
2
China
$4 Bn
5.5% a year · 8% of the world -
3
Canada
$4 Bn
4% a year · 8% of the world -
4
Japan
$3.1 Bn
4.5% a year · 6.2% of the world -
5
Germany
$1.8 Bn
2.2% a year · 3.7% of the world -
6
France
$1.4 Bn
3% a year · 2.8% of the world -
7
UK
$1.3 Bn
2% a year · 2.6% of the world -
8
Brazil
$1.2 Bn
5% a year · 2.5% of the world -
9
Italy
$1.2 Bn
3.5% a year · 2.4% of the world -
10
Ecuador
$990 Mn
4.6% a year · 2% of the world
Most clinical trials
Active trials by country (ClinicalTrials.gov)
See every trial on ClinicalTrials.gov (opens in a new tab)
SpainAsthma & COPD Drugs by country and region
India
Saudi Arabia
Mexico
Australia
South Africa
UAE
Egypt
Philippines
Malaysia
Hong Kong
Singapore
Thailand
Kenya
New Zealand
Russia"–" means we have no size for that place yet. 2033 values are projected from the 2023 size and the CAGR. Regions count only the countries we report on for trials.
Latest research 25,750 papers since 2021
- From Response to Remission in Adult Severe Asthma: Practical Clarifications Following the New American College of Chest Physicians Biologic Guideline. Chest, 2026
- Safety, Accuracy, Empathy, Information Quality, and Readability of Chronic Obstructive Pulmonary Disease Health Advice Generated by 6 Large Language Models: Cross-Sectional Comparative Evaluation Study. JMIR medical informatics, 2026
- Letter to the Editor: "Dissociation between Airflow and Lung Volume Responses following Triple Therapy Device Switching in Asthma-COPD Overlap". The American journal of the medical sciences, 2026
- KDM4B-PTX3-mediated dendritic cell senescence drives severe asthma and predicts biologic non-response. Journal of advanced research, 2026
- House dust mite sublingual immunotherapy and rhinitis-related quality of life in biologic-controlled severe asthma: A propensity score-matched real-world study. Respiratory medicine, 2026
Compare Asthma & COPD Drugs side by side
Key companies in Asthma & COPD Drugs
AstraZeneca Plc
Novartis AG
Boehringer Ingelheim GmbH
Merck & Co Inc
F. Hoffmann-La Roche Ltd
Quick answers
How big is the Asthma & COPD Drugs market?
The world Asthma & COPD Drugs market was worth about $49.5 Bn in 2023 and is projected to reach $73.3 Bn by 2033, growing 4% a year (CAGR).
Which country has the largest Asthma & COPD Drugs market?
The US is the largest of the 24 countries we cover, at $20.8 Bn in 2023. India grows fastest, at 7% a year.
How many clinical trials are running in Asthma & COPD Drugs?
ClinicalTrials.gov lists 1,336 active trials worldwide (recruiting, about to start or running), most of them in the US, as of 10 Nov 2026.
How much research is published on Asthma & COPD Drugs?
PubMed lists about 25,750 papers on the topic since 2021.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov. Research: PubMed (US National Library of Medicine). Fetched 10 Nov 2026. Trials and papers are found by search words, so counts are a guide.